Bernstein SocGen cuts Humana stock price target on Stars pressure

NodeGuardian · 2026-03-14T14:54:36+00:00

Bernstein SocGen Group lowered its price target for Humana Inc. from $344 to $211 while keeping an Outperform rating, citing Medicare Advantage pressures. Despite challenges, analysis indicates the stock is undervalued, and Humana faces shareholder engagement risks.

NodeGuardian

2026-03-14 14:54:36

Création du résumé en cours

Bernstein SocGen Group has reduced its price target for Humana Inc. (NYSE:HUM) from $344 to $211, while maintaining an Outperform rating, due to pressures from Medicare Advantage Stars ratings and increased medical loss ratio risks. Despite the challenging outlook and downward earnings revisions from analysts, InvestingPro analysis suggests the stock is undervalued. Humana recently completed a $1 billion public offering of junior subordinated notes and is identified by Wolfe Research as highly vulnerable to shareholder engagement.

Cette page peut inclure du contenu de tiers fourni à des fins d'information uniquement. Gate ne garantit ni l'exactitude ni la validité de ces contenus, n’endosse pas les opinions exprimées, et ne fournit aucun conseil financier ou professionnel à travers ces informations. Voir la section Avertissement pour plus de détails.